Summary:
In overweight or obese women with polycystic ovary syndrome (PCOS), combination therapy with semaglutide (1 mg weekly) and metformin (1000 mg twice daily) significantly reduced body weight, improved metabolic parameters, normalized reproductive hormone levels, and increased natural pregnancy rates compared to metformin monotherapy at 1000 mg twice daily, though it was associated with no major adverse effects reported in the abstract.
| PICO | Description |
|---|---|
| Population | Overweight or obese women diagnosed with PCOS based on Rotterdam criteria (n=100). |
| Intervention | Combination of metformin 1000 mg BID and semaglutide 1 mg once weekly for 16 weeks. |
| Comparison | Metformin monotherapy 1000 mg BID for 16 weeks. |
| Outcome | The combination group experienced greater reductions in body weight (-6.09 ± 3.34 kg vs. -2.25 ± 4.27 kg), BMI, waist-to-hip ratio, testosterone levels, CVAI, and CRP. Menstrual cycle recovery and natural pregnancy rates were significantly higher in the combination group (35% vs. 15%, P < 0.05). |
Source: Haiyan Chen, et al. “Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.” Read article here.
